|
Baseline characteristics for fluticasone and placebo groups. |
||
| Patients (n = 260) |
||
| Fluticasone n = 128 |
Placebo n = 132 |
|
|
|
||
| Age (years) (a) |
67.6 (8.9) |
67.3 (9.0) |
| Male n (%) (b) |
62 (48%) |
74 (56%) |
| Exacerbation history |
||
| Self-reported yearly COPD exacerbation rate |
1.93 (1.52) |
1.86 (1.57) |
| Antibiotics or steroids in last year(c) |
1.59 (1.71) |
1.48 (1.77) |
| Smoking Status |
||
| Current smoker n (%) |
52 (40.6%) |
47 (35.6%) |
| Amount smoked (pack years) |
40.0 (24.2) |
38.8 (22.3) |
| Medications |
||
| Duration of inhaled medications (years) |
8.7 (7.0) |
8.2 (5.6) |
| Daily Prescribed Dosage of ICS(d) (mcg) |
947 (784) |
812 (531) |
| On LABA medication n (%) |
45 (35.1%) |
42 (31.8%) |
| Influenza vaccine in winter |
104 (81.2%) |
106 (80.3%) |
| Lung Function |
||
| Pre bronchodilator FEV1 (litres) |
1.22 (0.54) |
1.32 (0.54) |
| Post bronchodilator FEV1 (litres) |
1.31 (0.55) |
1.40 (0.56) |
| Post bronchodilator FEV1 (% predicted) |
53.2 (18.2) |
55.0 (17.1) |
| Reversibility (% change in FEV1) |
8.1 (8.0) |
7.2 (6.8) |
| Post bronchodilator FVC (litres) |
2.40 (0.77) |
2.56 (0.88) |
| Peak expiratory flow rate (L/min) |
220 (90) |
235 (90) |
| Health Related Quality of Life |
||
| SGRQ Total (%) |
52.6 (20.2) |
47.2 (19.4) |
| EuroQol 5D total score |
0.64 (0.29) |
0.68 (0.30) |
| EuroQol 5D visual analogue scale |
60.6 (18.8) |
61.1 (20.8) |
| MRC Dyspnoea Scale |
||
| Scale 3 or greater (%) |
77 (60%) |
66 (50%) |
| Chronic Symptom Profile(d) |
||
| Shortness of Breath n (%) |
96 (75%) |
95 (72%) |
| Sputum Production n (%) |
69 (54%) |
78 (59%) |
| Wheeze n (%) |
60 (47%) |
59 (45%) |
| Cough n (%) |
72 (56%) |
69 (53%) |
|
(a) Continuous data is displayed as mean value and standard deviation. (b) Categorical data is displayed as number of cases (n) and percentage of group for fluticasone or placebo. (c) Patient prescriptions at general practice/hospital/accident and emergency/outpatient visits for antibiotics and/or steroids for COPD exacerbation. (d) Dosage of daily inhaled corticosteroid prescribed is stated a s beclomethasone equivalent in micrograms. (e) Chronic symptom profile at recruitment interview. LABA = Long acting beta 2 agonist. | ||
Choudhury et al. Respiratory Research 2007 8:93 doi:10.1186/1465-9921-8-93 |
||